Developing nanoparticle formulations or poorly soluble drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Developing nanoparticle formulations or poorly soluble drugs
Developing nanoparticle formulations of sparingly water-soluble drugs, such as Ketoconazole, Fenofibrate and Candesartan cilexetil, would enable the revival of these marketed products with improved bioavailability, reduced variability and convenient dosing regimen.


Pharmaceutical Technology Europe





Rapid advances in drug discovery have led to the identification of a number of compounds with good therapeutic potential. However, because of their complex chemistry, the majority of these compounds have poor aqueous solubility resulting in reduced and variable bioavailability.1–3 Current marketed formulations of sparingly water-soluble drugs such as Ketoconazole (KC), a imidazole antifungal agent used for treatment of fungal infections,4 Fenofibrate (FF), a fibric acid derivative used for the treatment of hypertriglyceridimia,5 and Candesartan cilexetil (CC) a non-peptide angiotensin II type 1 receptor antagonist used in the treatment of hypertension, are suboptimal.6 Following oral administration, absorption of these drugs from the gastrointestinal (GI) tract is dependent on their solubility in Gl fluids. Poorly soluble drugs generally have low dissolution velocity and exhibit a small concentration gradient across the intestinal mucosa, which can result in low, variable absorption and a poor therapeutic response.

Based on the understanding that the rate of drug dissolution is the primary driving force behind improved pharmacokinetic properties, these drugs were formulated as nanometer-sized particles — particles <1 μm. The increase in surface area because of the reduction in particle size can substantially increase dissolution rate if the formulation disperses into discrete particles.7

Nanocrystalline dispersion comprises drug, water and stabilizers. Stabilizers used to aid the dispersion of particles are either polymers and/or surfactants. Polymers act as the primary stabilizer whereas surfactants are used as the secondary stabilizer. To be effective, the stabilizers must wet the drug crystals and provide a steric and ionic barrier to prevent agglomeration. The concentration of polymeric stabilizers can range 1–10% w/v and the concentration of surfactants is generally <2% w/v.8 If required, other excipients, such as buffers, salts and diluents, such as sugar, can be added to enhance physical stability and further processing.


On the go...
The bead milling process used for the production of drug nanoparticles can be described as a simple procedure comprising attrition media, suspension and agitation. The extent of size reduction is governed by the grinding energy, which is determined by the intrinsic hardness of the drug, grinding media and milling power. The nanoparticulate dispersion was converted into solid intermediates for tabletting by granulating with water-soluble carriers. The dissolution characteristics of tablet formulations containing drug nanoparticles were compared with commercial formulations in physiologically relevant dissolution media.

Materials and methods

Materials. FF, KC and CC were procured from Dr. Reddy's Laboratories (India). Lactose monohydrate was purchased from Roquette Frères (France). Hydroxypropyl methylcellulose (HPMC, 6cps) was purchased from Colorcon (India). Sodium lauryl sulphate was purchased from Qualigen Fine Chemicals (India). Crospovidone (Polyplasdone) and sodium starch glycolate were obtained from International Specialty Products (Wayne, NJ, USA [ISP]) (USP) and Grain Processing Corp. (Muscatine, IA, USA), respectively. All other chemicals were of analytical reagent grade.

Preparation of nanosuspension on a laboratory scale. A glass apparatus mimicking the media milling machine was fabricated in-house for identifying the appropriate stabilizer, along with its concentration, for the preparation of nanoparticulate dispersions with adequate physical stability and the production of solid intermediates required for solid dosage form processing.9


ADVERTISEMENT

LCGC E-mail Newsletters
Subscribe:Check the box next to each newsletter you wish to subscribe for:
| Weekly
| Monthly
| Monthly | Weekly
 Name:
 E-mail:

Survey
At this month's AAPS Annual Meeting & Exposition, several graduate students were awarded as young innovators. What are your thoughts on innovation and the next generation?
We need more young innovators and more students enrolling in pharma science programs
Our industry has just the right mix of young and old to keep innovation going
Age is irrelevant when it comes to innovation
We need more young innovators and more students enrolling in pharma science programs
25%
Our industry has just the right mix of young and old to keep innovation going
16%
Age is irrelevant when it comes to innovation
59%
View Results
Jim MillerOutsourcing OutlookJim Miller Facing Reality
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advancing Chiral Chemistry in API Synthesis
Faiz kermaniSpotlightFaiz Kermani Demographic time bomb
Rx-360 Takes on Europe, Talks to PharmTech in Podcast Series
Sanctions, Not Barcodes
Vaccines Finding Their Way in Novel Applications
Genzyme’s Friday the 13th
DTCA: Beneficial or Harmful?
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here